Kiniksa Pharmaceuticals
Yahoo Finance • 4 months ago
Roth analysis: Has volatility created a trigger warning for stocks?
Investing.com - The financial markets have experienced a roller coaster ride of late, prompting analysts at Roth to issue a technical strategy update. Despite ending last week down just 0.04%, the S&P 500's minor dip feels like a victory... Full story
Yahoo Finance • 11 months ago
Investors in Kiniksa Pharmaceuticals (NASDAQ:KNSA) have seen returns of 30% over the past year
Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right individual stocks, you could make more than that. To wit, the Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) share price is... Full story
Yahoo Finance • last year
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8:30 a.m. Eastern Time to report its t... Full story
Yahoo Finance • last year
12 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into. If you want to skip our introduction to the biotechnology industry and how it might be affected by recent economic and stock market t... Full story
Yahoo Finance • last year
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
HAMILTON, Bermuda, July 18, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its seco... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time to report its first... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively – – ARCALYST full-year 2023 net product revenue expected to be $190 - $205 million, representing >60% year-over-year... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its... Full story
Yahoo Finance • 2 years ago
13 High Growth Pharma Stocks that are Profitable
In this piece, we will take a look at 13 high growth pharma stocks that are profitable. For more stocks, head on over to 5 High Growth Pharma Stocks that are Profitable. One industry that has rapidly evolved with time and impacted million... Full story
Yahoo Finance • 2 years ago
10 Best Healthcare Stocks For the Long Term
In this article, we will take a look at the 10 best healthcare stocks for the long term. You can skip this part and go to 5 Best Healthcare Stocks For the Long Term. The healthcare sector is one of those rare, evergreen areas of the indus... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively (unaudited) – – 2 of 3 cohorts enrolled in KPL-404 Phase 2 trial in rheumatoid arthritis; data expected in 1H 2024 –... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific T... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p<0.0001) – – KPL-404 Ph... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at 8:30 a.m. Eastern Time to report its... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, Augus... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Upfront and near-term proceeds of $100 million expected from vixarelimab global license agree... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
– Kiniksa to receive $100 million in upfront and near-term payments – – Kiniksa is eligible to receive development and commercial milestones as well as royalties on net sales – – Global license includes development and commercialization... Full story
Yahoo Finance • 2 years ago
Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, August 3, 2022, at 8:30 a.m. Eastern Time to report its... Full story
Yahoo Finance • 3 years ago
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Cash reserves expected to fund operations into at least 2024 – – Conference call and webcast... Full story
Yahoo Finance • 3 years ago
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
Kiniksa Pharmaceuticals, Ltd. HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. East... Full story
